Cellular Biomedicine Group (NASDAQ:CBMG) and CytRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Institutional and Insider Ownership
22.0% of Cellular Biomedicine Group shares are owned by institutional investors. Comparatively, 0.0% of CytRx shares are owned by institutional investors. 8.5% of Cellular Biomedicine Group shares are owned by company insiders. Comparatively, 22.0% of CytRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Cellular Biomedicine Group has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, CytRx has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Cellular Biomedicine Group and CytRx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Cellular Biomedicine Group | 0 | 1 | 0 | 0 | 2.00 |
CytRx | 0 | 0 | 0 | 0 | N/A |
Cellular Biomedicine Group currently has a consensus price target of $19.00, suggesting a potential downside of 3.80%. Given Cellular Biomedicine Group's higher probable upside, equities analysts plainly believe Cellular Biomedicine Group is more favorable than CytRx.
Earnings and Valuation
This table compares Cellular Biomedicine Group and CytRx's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Cellular Biomedicine Group | $340,000.00 | 1,131.44 | $-49,980,000.00 | N/A | N/A |
CytRx | $250,000.00 | 523.85 | $-7,160,000.00 | N/A | N/A |
CytRx has lower revenue, but higher earnings than Cellular Biomedicine Group.
Profitability
This table compares Cellular Biomedicine Group and CytRx's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Cellular Biomedicine Group | N/A | -144.80% | -61.68% |
CytRx | N/A | -62.90% | -50.65% |
Summary
CytRx beats Cellular Biomedicine Group on 5 of the 9 factors compared between the two stocks.